临床T1~3N1M0期乳腺癌新辅助化疗和改良根治术后腋窝淋巴结病理阴性患者术后放疗的价值

目的分析临床T1~3N1M0期乳腺癌患者经新辅助化疗(NAC)和改良根治术后达到腋窝淋巴结病理阴性(ypN0)患者术后放疗的价值和预后。方法回顾性分析1999—2013年中国医学科学院肿瘤医院收治的185例临床诊断为T1~3N1M0期乳腺癌患者的临床资料,所有患者均完成NAC和改良根治术,术后达ypN0。89例行术后放疗,96例未行放疗。Ⅱ期患者101例,Ⅲ期患者84例。采用Kaplan-Meier法计算局部区域复发率、远处转移率、无病生存率和总生存率,并行Log rank检验,单因素分析临床特征和治疗对患者预后的影响。结果全组患者的5年局部区域复发率、远处转移率、无病生存率和总生存率分别为4...

Full description

Saved in:
Bibliographic Details
Published in中华肿瘤杂志 Vol. 39; no. 6; pp. 445 - 452
Main Author 荣庆林 王淑莲 唐玉 金晶 宋永文 王维虎 刘跃平 房辉 任骅 刘新帆 余子豪 李晔雄
Format Journal Article
LanguageChinese
Published 100021,国家癌症中心 中国医学科学院北京协和医学院肿瘤医院放疗科 2017
Subjects
Online AccessGet full text
ISSN0253-3766
DOI10.3760/cma.j.issn.0253-3766.2017.06.009

Cover

Abstract 目的分析临床T1~3N1M0期乳腺癌患者经新辅助化疗(NAC)和改良根治术后达到腋窝淋巴结病理阴性(ypN0)患者术后放疗的价值和预后。方法回顾性分析1999—2013年中国医学科学院肿瘤医院收治的185例临床诊断为T1~3N1M0期乳腺癌患者的临床资料,所有患者均完成NAC和改良根治术,术后达ypN0。89例行术后放疗,96例未行放疗。Ⅱ期患者101例,Ⅲ期患者84例。采用Kaplan-Meier法计算局部区域复发率、远处转移率、无病生存率和总生存率,并行Log rank检验,单因素分析临床特征和治疗对患者预后的影响。结果全组患者的5年局部区域复发率、远处转移率、无病生存率和总生存率分别为4.5%、10.4%、86.6%和97.1%。放疗组和未放疗组患者的5年局部区域复发率分别为1.1%和7.5%,差异无统计学意义(P=0.071);5年远处转移率分别为5.1%和15.0%,差异有统计学意义(P=0.023);5年无病生存率分别为95.0%和79.0%,差异有统计学意义(P=0.008);5年总生存率分别为100.0%和94.5%,差异无统计学意义(P=0.089)。单因素分析结果显示,有无脉管瘤栓是影响患者5年局部区域复发率的主要因素(P=0.001),年龄和有无辅助放疗是影响患者5年远处转移率的主要因素(均P〈0.05),有无放疗是影响患者5年无病生存率的主要因素(P=0.008),病理T分期、原发灶NAC病理反应是影响患者5年总生存率的主要因素(均P〈0.05)。Ⅲ期患者中,放疗组和未放疗组患者的5年局部区域复发率分别为1.9%和14.4%,差异有统计学意义(P=0.041);5年无病生存率分别为91.9%和67.4%,差异有统计学意义(P=0.022)。Ⅱ期患者中,放疗组和未放疗组患者的5年远处转移率分别为0和11.5%,差异有统计学意义(P=0.044);5年无病生存率分别为100.0%和84.9%,差异有统计学意义(P=0.023)。结论临床T1~3N1M0期乳腺癌NAC和改良根治术后达到ypN0患者的的局部区域复发率较低,术后放疗能明显降低远处转移率并提高无病生存率,并且可以降低临床Ⅲ期患者的局部区域复发率。Ⅲ期患者需要术后放疗,Ⅱ期患者的放疗价值需要进一步研究。
AbstractList 目的 分析临床T1~3N1M0期乳腺癌患者经新辅助化疗(NAC)和改良根治术后达到腋窝淋巴结病理阴性(ypN0)患者术后放疗的价值和预后. 方法 回顾性分析1999-2013年中国医学科学院肿瘤医院收治的185例临床诊断为T1~3N1M0期乳腺癌患者的临床资料,所有患者均完成NAC和改良根治术,术后达ypN0.89例行术后放疗,96例未行放疗.Ⅱ期患者101例,Ⅲ期患者84例.采用Kaplan-Meier法计算局部区域复发率、远处转移率、无病生存率和总生存率,并行Log rank检验,单因素分析临床特征和治疗对患者预后的影响. 结果 全组患者的5年局部区域复发率、远处转移率、无病生存率和总生存率分别为4.5%、10.4%、86.6%和97.1%.放疗组和未放疗组患者的5年局部区域复发率分别为1.1%和7.5%,差异无统计学意义(P=0.071);5年远处转移率分别为5.1%和15.0%,差异有统计学意义(P=0.023);5年无病生存率分别为95.0%和79.0%,差异有统计学意义(P=0.008);5年总生存率分别为100.0%和94.5%,差异无统计学意义(P=0.089).单因素分析结果显示,有无脉管瘤栓是影响患者5年局部区域复发率的主要因素(P=0.001),年龄和有无辅助放疗是影响患者5年远处转移率的主要因素(均P<0.05),有无放疗是影响患者5年无病生存率的主要因素(P=0.008),病理T分期、原发灶NAC病理反应是影响患者5年总生存率的主要因素(均P<0.05).Ⅲ期患者中,放疗组和未放疗组患者的5年局部区域复发率分别为1.9%和14.4%,差异有统计学意义(P=0.041);5年无病生存率分别为91.9%和67.4%,差异有统计学意义(P=0.022).Ⅱ期患者中,放疗组和未放疗组患者的5年远处转移率分别为0和11.5%,差异有统计学意义(P=0.044);5年无病生存率分别为100.0%和84.9%,差异有统计学意义(P=0.023). 结论 临床T1~3N1M0期乳腺癌NAC和改良根治术后达到ypN0患者的的局部区域复发率较低,术后放疗能明显降低远处转移率并提高无病生存率,并且可以降低临床Ⅲ期患者的局部区域复发率.Ⅲ期患者需要术后放疗,Ⅱ期患者的放疗价值需要进一步研究.
目的分析临床T1~3N1M0期乳腺癌患者经新辅助化疗(NAC)和改良根治术后达到腋窝淋巴结病理阴性(ypN0)患者术后放疗的价值和预后。方法回顾性分析1999—2013年中国医学科学院肿瘤医院收治的185例临床诊断为T1~3N1M0期乳腺癌患者的临床资料,所有患者均完成NAC和改良根治术,术后达ypN0。89例行术后放疗,96例未行放疗。Ⅱ期患者101例,Ⅲ期患者84例。采用Kaplan-Meier法计算局部区域复发率、远处转移率、无病生存率和总生存率,并行Log rank检验,单因素分析临床特征和治疗对患者预后的影响。结果全组患者的5年局部区域复发率、远处转移率、无病生存率和总生存率分别为4.5%、10.4%、86.6%和97.1%。放疗组和未放疗组患者的5年局部区域复发率分别为1.1%和7.5%,差异无统计学意义(P=0.071);5年远处转移率分别为5.1%和15.0%,差异有统计学意义(P=0.023);5年无病生存率分别为95.0%和79.0%,差异有统计学意义(P=0.008);5年总生存率分别为100.0%和94.5%,差异无统计学意义(P=0.089)。单因素分析结果显示,有无脉管瘤栓是影响患者5年局部区域复发率的主要因素(P=0.001),年龄和有无辅助放疗是影响患者5年远处转移率的主要因素(均P〈0.05),有无放疗是影响患者5年无病生存率的主要因素(P=0.008),病理T分期、原发灶NAC病理反应是影响患者5年总生存率的主要因素(均P〈0.05)。Ⅲ期患者中,放疗组和未放疗组患者的5年局部区域复发率分别为1.9%和14.4%,差异有统计学意义(P=0.041);5年无病生存率分别为91.9%和67.4%,差异有统计学意义(P=0.022)。Ⅱ期患者中,放疗组和未放疗组患者的5年远处转移率分别为0和11.5%,差异有统计学意义(P=0.044);5年无病生存率分别为100.0%和84.9%,差异有统计学意义(P=0.023)。结论临床T1~3N1M0期乳腺癌NAC和改良根治术后达到ypN0患者的的局部区域复发率较低,术后放疗能明显降低远处转移率并提高无病生存率,并且可以降低临床Ⅲ期患者的局部区域复发率。Ⅲ期患者需要术后放疗,Ⅱ期患者的放疗价值需要进一步研究。
Abstract_FL Objective To analyze the outcomes of clinical T1-3N1M0 breast cancer patients with pathological negative axillary lymph nodes (ypN0) after neoadjuvant chemotherapy (NAC) and mastectomy, and investigate the role of postmastectomy radiotherapy (PMRT).Methods A total of 185 patients with clinical T1-3N1M0 breast cancer treated between 1999 and 2013 were retrospectively reviewed.All patients were treated with NAC and mastectomy, and achieved ypN0.Of them, 89 patients received additional PMRT and 96 patients did not.101 patients had clinical stage Ⅱ disease.84 patients had clinical stage Ⅲ disease.The rates of locoregional recurrence (LRR), distant metastasis (DM), disease-free survival (DFS), and overall survival (OS) were calculated using the Kaplan-Meier method, and differences were compared using the log-rank test.Univariate analysis was used to interpret the impact of clinical features and treatment on patients′ outcome.Results The 5-year rates of LRR, DM, DFS, and OS for all patients were 4.5%, 10.4%, 86.6%, and 97.1%, respectively.For patients with and without PMRT, the 5-year LRR rates were 1.1% and 7.5% (P=0.071), the 5-year DM rates were 5.1% and 15.0% (P=0.023), the 5-year DFS rates were 95.0% and 79.0% (P=0.008), and the 5-year OS rates were 100.0% and 94.5% (P=0.089) respectively.In univariate analysis, lymph-vascular space invasion (LVSI) was poor prognostic factor of LRR (P=0.001), < 40 years old and lack of PMRT was a poor prognostic factor for DM (P<0.05), lack of PMRT was a poor prognostic factor for DFS (P=0.008), primary lesion residual and mild-moderate pathological response to NAC were poor prognostic factors for OS (P<0.05).In the subgroup of Stage Ⅲ disease, for patients with and without PMRT, the 5-year LRR rates were 1.9% and 14.4% (P=0.041), the 5-year DFS rates were 91.9% and 67.4% (P=0.022), respectively.In the subgroup of Stage Ⅱ disease, for patients with and without PMRT, the 5-year DM rates were 0 and 11.5% (P=0.044), the 5-year DFS rates were 100.0% and 84.9% (P=0.023), respectively.Conclusions The LRR rate of clinical T1-3N1M0 breast cancer patients who achieved ypN0 after NAC and mastectomy was low.PMRT decreased the DM rate and increased DFS rate in all patients, and significantly decreased the LRR rate in Stage Ⅲ disease.PMRT should be considered for patients with Stage Ⅲ disease, and further research is warranted to investigate the benefit of PMRT for Stage Ⅱ disease.
Author 荣庆林 王淑莲 唐玉 金晶 宋永文 王维虎 刘跃平 房辉 任骅 刘新帆 余子豪 李晔雄
AuthorAffiliation 国家癌症中心中国医学科学院北京协和医学院肿瘤医院放疗科,100021
AuthorAffiliation_xml – name: 100021,国家癌症中心 中国医学科学院北京协和医学院肿瘤医院放疗科
Author_FL Wang Weihu
Yu Zihao
Song Yongwen
Liu Yueping
Rong Qinglin
Tang Yu
Wang Shulian
Jin Jing
Ren Hua
Liu Xinfan
Li Yexiong
Fang Hui
Author_FL_xml – sequence: 1
  fullname: Rong Qinglin
– sequence: 2
  fullname: Wang Shulian
– sequence: 3
  fullname: Tang Yu
– sequence: 4
  fullname: Jin Jing
– sequence: 5
  fullname: Song Yongwen
– sequence: 6
  fullname: Wang Weihu
– sequence: 7
  fullname: Liu Yueping
– sequence: 8
  fullname: Fang Hui
– sequence: 9
  fullname: Ren Hua
– sequence: 10
  fullname: Liu Xinfan
– sequence: 11
  fullname: Yu Zihao
– sequence: 12
  fullname: Li Yexiong
Author_xml – sequence: 1
  fullname: 荣庆林 王淑莲 唐玉 金晶 宋永文 王维虎 刘跃平 房辉 任骅 刘新帆 余子豪 李晔雄
BookMark eNo90E1LAlEUBuC7MMjKPxEEbZzO9Y53ZpYhfYHVxr3cGR0_0LEcKnIl0QSphJRohX1Ai6iNUYKp5a9x7kyr_kITRpzFgZeH98CZQT6jYCQRWsQgEInCkpZnQlbImKYhQChMgl5IhRBgSQAqACg-5P_Pp1HANDMqhDGhMsHUj_bH7117UInh789bsoU3gbfvxv031xo4VzXefHFHll15smtNp9myz2u80XdPO_y-z1-HvN2x62euVXWeb3ivave6zvDCaVlO_eTrssvLj_zowS1bE8YbI6_BuT4eD3t2-WMOTeksZyYDf3sWxVZXYpH1YHR7bSOyHA1qYQmCClZEWaNUJQlVUimIapJRjSoKEJEwVZSAKbqu6QldBTWkMCBSGFMPJpSklsCYzKKFSe0BM3RmpOLZwl7R8A7GS-lS7vdJQAGD5-YnTksXjNRuxpM7xUyeFQ_jVAqJ3sgy-QGvw5Wp
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2RA
92L
CQIGP
W91
~WA
2B.
4A8
92I
93N
PSX
TCJ
DOI 10.3760/cma.j.issn.0253-3766.2017.06.009
DatabaseName 维普期刊资源整合服务平台
中文科技期刊数据库-CALIS站点
维普中文期刊数据库
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy
DocumentTitle_FL The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy
EndPage 452
ExternalDocumentID zhzl201706010
672424288
GrantInformation_xml – fundername: 国家重大研发计划; National Key Projects of Research and Development
  funderid: (2016YFC0904600); (2016YFC0904600)
GroupedDBID ---
-05
123
2B.
2C~
2RA
92F
92I
92L
ABDBF
ACGFS
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CIEJG
CQIGP
CW9
EOJEC
OBODZ
TCJ
TGQ
U1G
U5O
W91
~WA
4A8
93N
ABJNI
ACUHS
PSX
ID FETCH-LOGICAL-c570-91948c66b3db7b604bea6c6990343ab470a9ffcfdfb0b29a037516b60d9ecd113
ISSN 0253-3766
IngestDate Thu May 29 04:00:01 EDT 2025
Wed Feb 14 10:00:20 EST 2024
IsPeerReviewed false
IsScholarly true
Issue 6
Keywords 乳腺肿瘤
药物疗法
Prognosis
预后
放射疗法
Breast neoplasms
Drug therapy
Radiotherapy
Language Chinese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c570-91948c66b3db7b604bea6c6990343ab470a9ffcfdfb0b29a037516b60d9ecd113
Notes Rong Qinglin, Wang Shulian, Tang Yu, Jin Jing, Song Yongwen, Wang Weihu, Liu Yueping, Fang Hui, Ren Hua, Liu Xinfan, Yu Zihao, Li Yexiong(Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Belting, 100021, China)
Breast neoplasms ; Drug therapy ; Radiotherapy ; Prognosis
ObjectiveTo analyze the outcomes of clinical T1-3N1M0 breast cancer patients with pathological negative axillary lymph nodes (ypN0) after neoadjuvant chemotherapy (NAC) and mastectomy, and investigate the role of postmastectomy radiotherapy (PMRT). MethodsA total of 185 patients with clinical T1-3N1M0 breast cancer treated between 1999 and 2013 were retrospectively reviewed. All patients were treated with NAC and mastectomy, and achieved ypN0. Of them, 89 patients received additional PMRT and 96 patients did not. 101 patients had clinical stage Ⅱ disease. 84 patients had clinical stage Ⅲ disease. The rates of locoregional recurrence (LRR), distant metas
PageCount 8
ParticipantIDs wanfang_journals_zhzl201706010
chongqing_primary_672424288
PublicationCentury 2000
PublicationDate 2017
PublicationDateYYYYMMDD 2017-01-01
PublicationDate_xml – year: 2017
  text: 2017
PublicationDecade 2010
PublicationTitle 中华肿瘤杂志
PublicationTitleAlternate Chinese Journal of Oncology
PublicationTitle_FL Chinese Journal of Oncology
PublicationYear 2017
Publisher 100021,国家癌症中心 中国医学科学院北京协和医学院肿瘤医院放疗科
Publisher_xml – name: 100021,国家癌症中心 中国医学科学院北京协和医学院肿瘤医院放疗科
SSID ssib051368316
ssib007279245
ssib000995398
ssj0042033
ssib017477325
ssib006576341
ssib001103529
ssib058574917
Score 2.1507103
Snippet ...
目的 分析临床T1~3N1M0期乳腺癌患者经新辅助化疗(NAC)和改良根治术后达到腋窝淋巴结病理阴性(ypN0)患者术后放疗的价值和预后. 方法...
SourceID wanfang
chongqing
SourceType Aggregation Database
Publisher
StartPage 445
SubjectTerms 乳腺肿瘤
放射疗法
药物疗法
预后
Title 临床T1~3N1M0期乳腺癌新辅助化疗和改良根治术后腋窝淋巴结病理阴性患者术后放疗的价值
URI http://lib.cqvip.com/qk/93685X/201706/672424288.html
https://d.wanfangdata.com.cn/periodical/zhzl201706010
Volume 39
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LitRAMMgK4kUUFd94sEGQWZN00uk-dmYyiKCnEbwtecy4iM76WC97kEUcQV3EF-sDRcGD6EXRhXVd8Wt2MuNfWFWdyWRdwcdlaKqrquvR6a5Kumss6wgsjJnInLTmZapdgyexXYsl57UY8DM7y1KH493hU6fFiTPeybP-2U0TDyqnlq7NJpPp3G_vlfyPVwEGfsVbsv_g2ZIpAKAN_oVf8DD8_pWPWeSxULLQY5HPQs2kbjksiPhp55TNIsFUnakmISkWchZJJgkvCphSTNYJR7DQxq4wwl5gJDXTihp17EVkQAsQotwRFfFEhorpJkK0TRDg5rIwLEbHLqCymYyK0WWIDLVmqkHIAUF8bKAaAdIqToMGJE9A5CCGYsqoKvB0hg6o4TJt9LIJeeOgRtSoogU0wFIemSXEcVFTEL5ejdMLy-oG9TZG8oNqTeIAXSQJaAFAlL_JVLmlE26DRDN-EYQbrUMJkKkMCysoh4giMN8YxUfhQZECV417wHuGRqAnQ1F9eWNuqdKDhp9VXNir6sQLtCV9NIwiKpPA2DpYpzPoI_mxdaCSHmhCchrANTHSRpgSopC1dkeTyLCGaVUfmbNZmU0bGZbkG01eIpc4v_MwyVPZ41yf4x4nqhuyqW5VLDzV3dUzlUeLQM0zpY9_jQHwlBc8uOnFePI8DTJZDoInOQMq12urcfxTnkqdm5674Jp6Unhpc7MLJO6EtVmHjbBZyUmUX62ZCfEzJDHjnEBABs8rOUaAJTrHn-59hwvJxzkZpOuBR-9MTPjouTanYzEjobdYRwutjv9JJ6wPMz3TPXcZol66hNjtxN1zlXi5td3aViS6h7VZtXZYm-amd1qza1-W-l_vtJzrtEblL16trXwe9r4Oni3kix-H33v9O-_6C4uDxSf9hwv545Xh7Q_565X802r-4kP__r1h7-7g_ct8-W5_eWmw-mjwpDe4f-vH06V8_m1-481wvmfQ8sffgcPg-c211eX-_LddVqsZteonasX_vtRSP7Ah_FKeTIVIsPR7ImwvacciFRA2c4_HiRfYsep00k7WSezEVTH-i7cjABF2mzRzHL7bmujOdNt7rMN26sWO2-YihbyPp5nsuHjLtJPIWGS-295r7S8NNnXJlPeZEgFemXOl3GsdKkw4VSz6V6fWzZF9f0LYb23Ftnlle8CamL1yrX0QkpjZ5FAxrX4C6m4Brg
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E4%B8%B4%E5%BA%8AT1%7E3N1M0%E6%9C%9F%E4%B9%B3%E8%85%BA%E7%99%8C%E6%96%B0%E8%BE%85%E5%8A%A9%E5%8C%96%E7%96%97%E5%92%8C%E6%94%B9%E8%89%AF%E6%A0%B9%E6%B2%BB%E6%9C%AF%E5%90%8E%E8%85%8B%E7%AA%9D%E6%B7%8B%E5%B7%B4%E7%BB%93%E7%97%85%E7%90%86%E9%98%B4%E6%80%A7%E6%82%A3%E8%80%85%E6%9C%AF%E5%90%8E%E6%94%BE%E7%96%97%E7%9A%84%E4%BB%B7%E5%80%BC&rft.jtitle=%E4%B8%AD%E5%8D%8E%E8%82%BF%E7%98%A4%E6%9D%82%E5%BF%97&rft.au=%E8%8D%A3%E5%BA%86%E6%9E%97&rft.au=%E7%8E%8B%E6%B7%91%E8%8E%B2&rft.au=%E5%94%90%E7%8E%89&rft.au=%E9%87%91%E6%99%B6&rft.date=2017&rft.pub=100021%2C%E5%9B%BD%E5%AE%B6%E7%99%8C%E7%97%87%E4%B8%AD%E5%BF%83+%E4%B8%AD%E5%9B%BD%E5%8C%BB%E5%AD%A6%E7%A7%91%E5%AD%A6%E9%99%A2%E5%8C%97%E4%BA%AC%E5%8D%8F%E5%92%8C%E5%8C%BB%E5%AD%A6%E9%99%A2%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2%E6%94%BE%E7%96%97%E7%A7%91&rft.issn=0253-3766&rft.volume=39&rft.issue=6&rft.spage=445&rft.epage=452&rft_id=info:doi/10.3760%2Fcma.j.issn.0253-3766.2017.06.009&rft.externalDocID=zhzl201706010
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F93685X%2F93685X.jpg
http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhzl%2Fzhzl.jpg